AnGes, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2019
April 22, 2019 at 08:58 am EDT
Share
AnGes, Inc. announced consolidated earnings results for the first quarter ended March 31, 2019. For the period, the consolidated company reported net sales of goods of JPY 75 million against JPY 73 million a year ago. Operating loss was JPY 918 million against JPY 590 million a year ago. Ordinary loss was JPY 938 million against JPY 587 million a year ago. Net loss was JPY 1,183 million or JPY 11.92 per share against JPY 537 million or JPY 6.67 per share a year ago.
The consolidated company expects net sales of JPY 335 million, operating loss of JPY 2,800 million, ordinary loss of JPY 2,800 million, net loss of JPY 2,800 million or net loss per share of JPY 27.4 for the fiscal year ending December 31, 2019.
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
AnGes, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2019
ANGES, INC. 
